<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076071</url>
  </required_header>
  <id_info>
    <org_study_id>SunYat-sen U</org_study_id>
    <nct_id>NCT05076071</nct_id>
  </id_info>
  <brief_title>Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors</brief_title>
  <official_title>Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors: A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yizhuo Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Samples of 200 patients with pediatric malignant solid tumors will prospectively be&#xD;
      collected. Selected samples are sufficient for next generation sequencing(NGS) and available&#xD;
      for follow-up information. Multi-omics techniques such as DNA and RNA panel will be used to&#xD;
      study driver genes for the development of malignant solid tumors in children, and to explore&#xD;
      the pathogenic mechanism. The aim of this study is to explore new biomarkers for the&#xD;
      diagnosis and treatment for childhood malignant solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DNA and RNA extracted from tumor tissues and leukocytes will be analyzed by Onco&#xD;
      PanScan/whole exon sequencing(Genetronhealth), and comprehensive gene mutation information&#xD;
      such as single nucleotide variation, insertion deletion mutation, gene copy number variants&#xD;
      and structure variants will be obtained.&#xD;
&#xD;
      Through in-depth mining of genomic data generated by clinical tumor tissue detection, the&#xD;
      differences among different subtypes of pediatric solid tumors in TCGA data will be compared&#xD;
      with previous studies. Combined with clinical pathological and molecular subtyping results,&#xD;
      auxiliary diagnosis was performed. Analyzing therapeutic targets and identifying pathogenic&#xD;
      cancer-predisposing variants may provide molecular reference for children's malignant solid&#xD;
      tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">August 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mutation characteristics of malignant solid tumors in Chinese children.</measure>
    <time_frame>2021.8-2023.8</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pediatric, Solid Tumors, NGS</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>NGS</intervention_name>
    <description>Next Generation Sequencing</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        200&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are diagnosed by histology and pathology as pediatric malignant solid tumors&#xD;
             (including soft tissue sarcoma, osteosarcoma, pediatric glioma, neuroblastoma,&#xD;
             nephroblastoma, retinoblastoma, hepatoblastoma, atypical teratoid/rhabdomymoma,&#xD;
             embryonal tumor, etc.);&#xD;
&#xD;
          2. Age: &lt; 18 years old;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) PS score: 0-2, estimated survival &gt;6 months;&#xD;
&#xD;
          4. Complete clinical laboratory examination and pathological examination information of&#xD;
             patients;&#xD;
&#xD;
          5. Patients can be evaluated on time, and samples can be obtained throughout the whole&#xD;
             test process;&#xD;
&#xD;
          6. Informed consent signed by the patient or his/her legal representative shall be&#xD;
             obtained after the patient is informed of the project;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. As determined by the investigator, the patient had other major diseases that might&#xD;
             affect follow-up and short-term survival;&#xD;
&#xD;
          2. Any social/psychological problems that the researcher determines are not suitable for&#xD;
             the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>suying lu</last_name>
    <phone>+8613570435681</phone>
    <email>lusy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Zhuo Zhang, MD</last_name>
      <phone>18622221239</phone>
      <email>zhangyzh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yi-Zhuo Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yizhuo Zhang</investigator_full_name>
    <investigator_title>proffesor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

